Contract manufacturer CMC Biologics has ramped-up bioreactor capacity to meet demand for biologic drugs for Phase III clinical trials and beyond.
The Danish contract manufacturing and development organisation (CDMO) has installed a 2,000 litre Thermo Scientific HyClone single-use bioreactor (SUB) at its manufacturing facility in Copenhagen, which it aims to have up and running by December.
Gustavo Mahler, COO of CMC Biologics, said: "The expansion of the facility to include the 2,000L SUB will allow us to meet increasing demand for producing biologicals for Phase III and into market supply.”
Mahler added: "We have worked closely with Thermo Fisher Scientific to bring this project in on time and on budget."
The investment comes just over a year after CMC boosted bioreactor capacity at its manufacturing facility in Seattle, Washington in a move that also involved close collaboration with Thermo Fisher.
Cell line licensing
It also follows hot on the heels of CMC’s deal with Oxford BioTherapeutics (OBT), which saw the Danish CDMO grant the UK developer access to its CHEF1 cell line-based expression system for drug research and development applications.
At the time OBT said it would use the expression technology to further the development of candidate anticancer antibodies in its OGAP proteome database.
Jon Terrett, OBT's Chief Scientific Officer, said: “By licensing industry-leading technologies, such as the CHEF1 system, OBT further increases its research and development capabilities in line with our strategy to advance our pipeline of therapeutic antibodies toward clinical development.”